Olema Pharmaceuticals (OLMA) Operating Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Operating Expenses for 7 consecutive years, with $58.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 66.28% year-over-year to $58.0 million; the TTM figure through Mar 2026 stood at $201.8 million (up 41.33% YoY), while the FY2025 annual figure was $178.7 million, up 25.62% from the prior year.
• Operating Expenses climbed to $58.0 million in Q1 2026 per OLMA's latest filing, from $50.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $58.0 million in Q1 2026 and bottomed at $21.6 million in Q2 2023.
• Historically, Operating Expenses has averaged $34.8 million across 5 years, with a median of $33.5 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 101.51% — and 2023, when it tumbled 35.12%.
• Olema Pharmaceuticals' Operating Expenses stood at $27.2 million in 2022, then climbed by 11.75% to $30.4 million in 2023, then advanced by 20.88% to $36.8 million in 2024, then soared by 36.22% to $50.1 million in 2025, then grew by 15.78% to $58.0 million in 2026.
• Business Quant data shows OLMA's Operating Expenses at $58.0 million in Q1 2026, $50.1 million in Q4 2025, and $45.9 million in Q3 2025.